Terms: = Ovarian epithelial cancer AND MUC16, CA125, CA-125 AND Clinical Outcome
27 results:
1. High grade, advanced, serous ovarian cancer with low serum ca125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract] [Full Text] [Related]
2. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
[TBL] [Abstract] [Full Text] [Related]
3. Perioperative change in ca125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer.
Timmermans M; Zwakman N; Sonke GS; Van de Vijver KK; Duk MJ; van der Aa MA; Kruitwagen RF
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():364-369. PubMed ID: 31400565
[TBL] [Abstract] [Full Text] [Related]
4. GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with ca125 in epithelial ovarian cancer.
Zhao D; Wang X; Zhang W
BMC Cancer; 2018 Mar; 18(1):328. PubMed ID: 29580231
[TBL] [Abstract] [Full Text] [Related]
5. TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Park GB; Kim D
Oncol Rep; 2017 Nov; 38(5):3167-3176. PubMed ID: 28901470
[TBL] [Abstract] [Full Text] [Related]
6. LAMP3 expression correlated with poor clinical outcome in human ovarian cancer.
Wang D; Cao X; Zhang Y; Liu Y; Yao C; Ge W; Xu Y
Tumour Biol; 2017 Mar; 39(3):1010428317695014. PubMed ID: 28349821
[TBL] [Abstract] [Full Text] [Related]
7. Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer.
Huang CY; Yang YC; Wang KL; Chen TC; Chen JR; Weng CS; Chien HJ; Chang CL
Taiwan J Obstet Gynecol; 2016 Jun; 55(3):405-9. PubMed ID: 27343324
[TBL] [Abstract] [Full Text] [Related]
8. The prognostic value of pretreatment ca-125 levels and ca-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study.
Bai H; Sha G; Xiao M; Gao H; Cao D; Yang J; Chen J; Wang Y; Zhang Z; Shen K
Oncotarget; 2016 Mar; 7(13):15566-76. PubMed ID: 26863639
[TBL] [Abstract] [Full Text] [Related]
9. Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome.
Leng R; Liao G; Wang H; Kuang J; Tang L
Med Oncol; 2015 Feb; 32(2):329. PubMed ID: 25585684
[TBL] [Abstract] [Full Text] [Related]
10. Serum HE4 and ca125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
[TBL] [Abstract] [Full Text] [Related]
11. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.
Braicu EI; Fotopoulou C; Van Gorp T; Richter R; Chekerov R; Hall C; Butz H; Castillo-Tong DC; Mahner S; Zeillinger R; Concin N; Vergote I; Sehouli J
Gynecol Oncol; 2013 Feb; 128(2):245-51. PubMed ID: 23178313
[TBL] [Abstract] [Full Text] [Related]
12. [Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Zhao D; Wu LY; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):855-8. PubMed ID: 21223693
[TBL] [Abstract] [Full Text] [Related]
13. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.
Mahner S; Woelber L; Eulenburg C; Schwarz J; Carney W; Jaenicke F; Milde-Langosch K; Mueller V
BMC Cancer; 2010 Apr; 10():139. PubMed ID: 20388222
[TBL] [Abstract] [Full Text] [Related]
14. Development of a multimarker assay for early detection of ovarian cancer.
Yurkovetsky Z; Skates S; Lomakin A; Nolen B; Pulsipher T; Modugno F; Marks J; Godwin A; Gorelik E; Jacobs I; Menon U; Lu K; Badgwell D; Bast RC; Lokshin AE
J Clin Oncol; 2010 May; 28(13):2159-66. PubMed ID: 20368574
[TBL] [Abstract] [Full Text] [Related]
15. Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.
Pölcher M; Braun M; Friedrichs N; Rudlowski C; Bercht E; Fimmers R; Sauerwald A; Keyver-Paik MD; Kübler K; Büttner R; Kuhn WC; Hernando JJ
Cancer Immunol Immunother; 2010 Jun; 59(6):909-19. PubMed ID: 20087581
[TBL] [Abstract] [Full Text] [Related]
16. Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.
Woelber L; Mueller V; Eulenburg C; Schwarz J; Carney W; Jaenicke F; Milde-Langosch K; Mahner S
Gynecol Oncol; 2010 May; 117(2):183-8. PubMed ID: 20051287
[TBL] [Abstract] [Full Text] [Related]
17. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer.
Gadducci A; Cosio S; Tana R; Genazzani AR
Crit Rev Oncol Hematol; 2009 Jan; 69(1):12-27. PubMed ID: 18595727
[TBL] [Abstract] [Full Text] [Related]
18. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.
Cho H; Hur HW; Kim SW; Kim SH; Kim JH; Kim YT; Lee K
Cancer Immunol Immunother; 2009 Jan; 58(1):15-23. PubMed ID: 18414853
[TBL] [Abstract] [Full Text] [Related]
19. Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.
O'Connor JP; Jayson GC; Jackson A; Ghiorghiu D; Carrington BM; Rose CJ; Mills SJ; Swindell R; Roberts C; Mitchell CL; Parker GJ
Clin Cancer Res; 2007 Oct; 13(20):6130-5. PubMed ID: 17947478
[TBL] [Abstract] [Full Text] [Related]
20. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor.
Huang CY; Cheng WF; Lee CN; Su YN; Chien SC; Tzeng YL; Hsieh CY; Chen CA
Anticancer Res; 2006; 26(6C):4721-8. PubMed ID: 17214332
[TBL] [Abstract] [Full Text] [Related]
[Next]
